Probiotics: The mood alleviating elixir to combat depression or an overrated additive with intangible effects.
Category: #health  By Dhananjay Punekar  Date: 2017-06-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Probiotics: The mood alleviating elixir to combat depression or an overrated additive with intangible effects.

A new scientific research study has recently stated that consuming a specific type of probiotic is likely to help battle both - the symptoms of depression and irritable bowel syndrome (IBS). Researchers claim that this is a revolutionary discovery that may transform the dynamics of the medical sector with respect to psychiatric disorders and functional bowel diseases.

As per reliable sources, the masses have been experiencing a heightened sense of awareness regarding the benefits of probiotics for various bowel related disorders. In order to verify whether the consumption of probiotics promises positive outcomes or not, eminent researchers recently conducted a 10 week study program. The program apparently included the participation of 44 people who underwent two different ways of treatment pertaining to the disorders they suffered from.

Around 50% of the do-gooders consumed a daily dose of placebo, while the other 50% consumed a daily dosage of a strong probiotic. More than five and a half weeks later, it was observed that 22% of the people on the placebo had reduced depression symptoms, while a whopping 64% of the people on the probiotic had a decreased depression score.

One of the senior officials who conducted the study has reportedly stated that this research will open up a new line of treatment for psychiatric ailments as well as bowel disorders. Experts predict that this research will also positively impel global probiotics market share over the next few years.

While the above research study has provided ample evidence regarding the positive effects of probiotics on depression, the medical community demands a more stringent, closely-guarded set of experiments to be undertaken on similar lines. The limited sample space considered may have impacted negatively on the result interpretation, as sufficient data has been unavailable to carry out the post processing of the results. As per experts, brain scanning is deemed another way to monitor the effects of probiotic supplements on human behavior. However, it is rather difficult to predict which way of treatment has exactly influenced the diseases. Brain scanning provides a pattern of mood fluctuations in the brain areas. The results obtained during this scanning make for an interesting case study, however, they are not very conclusive.

Due to the lack of evidence regarding the available iterative results, researchers are still in the nascent stages of this investigation. The research regarding the use of probiotics supplement needs a strong result oriented backing to prove the effectiveness of the product on IBS and depression.

Medical research calls for a mature assessment regarding the effects of probiotic supplement on a person’s mood and behavioral patterns. In the event that the proposed R&D activities bear fruit and the scientific community is bestowed with positive, effective outcomes, pharmaceutical companies can expect lucrative opportunities not only for themselves, but also for the patients suffering from bowel disorders and psychiatric diseases.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...